



Press release

March 30, 2023

## Affibody appoints Peter Zerhouni as CBO

- *Peter Zerhouni joins as Chief Business Officer on April 3, 2023.*

**Solna, Sweden, March 30, 2023** - Affibody AB ("Affibody") today announced the appointment of Peter Zerhouni as CBO. He will join the Affibody management team and will be responsible for business and corporate development. This appointment strengthens the leadership of key corporate functions as the company enters its next stage of development.

*"We are pleased to welcome Peter to Affibody. His substantial experience from business and corporate development will strengthen our organization at a key point in time as our promising portfolio is moving into late-stage development and multiple business and commercial opportunities are emerging,"* said David Bejker, CEO.

Peter Zerhouni joins Affibody from a role as Senior Advisor Business Development at BioArctic. Prior to that he served as CEO of InDex Pharmaceuticals where he was responsible for taking the company public and raising more than USD 100 million in public financings. He also led the development of InDex's lead asset through Phase 2 and into Phase 3, as well as preparing for commercialization and launch. Prior to that he was with Diamyd Medical both as President and CEO and Director of Business Development. During his time at Diamyd he was responsible for leading the business development efforts that eventually led to a USD 625 million partnership with Johnson & Johnson. Earlier in his career he worked at the global financial institution ING Group.

He holds a MSc in Biology and a BSc in Business Administration and Economics from Lund University and he has also studied at University of California at Berkeley.

### **About Affibody**

Affibody is a clinical-stage integrated biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next-generation biopharmaceutical drugs based on its unique proprietary technology platform, Affibody® molecules. Through its validated business model, the company has a proven capability of identifying and prioritizing strategic projects in a timely and de-risked way. Affibody has established several partnerships for the development and commercialization of its innovations with international pharmaceutical companies. Affibody's main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: [www.affibody.com](http://www.affibody.com)

**Disclaimer**

This press release contains forward-looking statements. While Affibody consider the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by several hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

**Contacts:**

**Affibody**

David Bejker, CEO	+46 706 454 948
Camilla Danell, CFO	+46 761 148 910

**Affibody Investor Contact**

Alexandra Roy	<a href="mailto:aroy@soleburytrout.com">aroy@soleburytrout.com</a>
---------------	--

**Affibody Media Contact**

Richard Hayhurst/Ola Bjorkman RHA Communications	+44 7711 821 527 <a href="mailto:richard@rhacomms.eu">richard@rhacomms.eu</a>
---	--